The CVTAG Meeting Minutes give an interesting view into the development of the protocols that were experienced by New Zealanders as relate to Covid Vaccination.
Let’s take a stroll down memory lane…
Meeting 5 February 2021 (Wayback Link)
Purpose of report: To outline the COVID-19 Vaccine Technical Advisory Group’s recommendations on for whom
the Pfizer mRNA COVID-19 vaccine is appropriate.
It’s interesting to note that under-16s were not considered to be eligible at this point, but they “may need to be considered” if an outbreak happened at a School.
More interestingly: Pregnant women need to discuss risk/benefit with a health professional.
More interestingly still: If the vaccinee was on one of a number of drugs that treat a range of Cancers (melanoma, renal cell carcinoma, lung, kidney, bladder, head and neck, cervical, colorectal cancers, non-small cell lung cancer (NSCLC), small-cell lung cancer (ES-SCLC), hepatocellular carcinoma and triple-negative breast cancers, they should get advice from their specialist. No word on what that advice is, in this early stage.
Vaccinees should be monitored for 30 minutes in case of Anaphylaxis.
Meeting 8 March 2021 – (Wayback Link)
Purpose of report: To outline the COVID-19 Vaccine Technical Advisory Group’s recommendation following a
request to reconsider the current requirement for individuals to be observed for 30 minutes
after receiving the Pfizer COVID-19 vaccine.
Essentially, CVIP asked CVTAG to advise on whether the 30 minute observation window could be lowered. They said it could to 20 minutes.
Meeting 17 March 2021 – (Wayback Link)
This was about which comorbidities saw worse outcomes if the person caught Covid, therefore who should be prioritised.
Note the exclusion of pregnant women.
Meeting 17 March 2021 – (Wayback Link)
The CVTAG was asked (by Te Ahu o Te Kahu (Cancer Control Agency) and the Immunisation Advisory Center about removing the advice previously given to people taking the earlier Cancer treatments to consult with a specialist before taking the Covid-19 vaccine from public display, despite “limited data specifically with regards to the Pfizer/BioNTech Covid-19 vaccine and oncology populations.
CVTAG advised removal from both Training Materials, and Public-facing Material.
More to come.
